## LISTING OF CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

1-8. (Cancelled).

9. (Currently amended): A diagnostic method for asymptomatic cerebral infarction, comprising:

(a) obtaining at least one biological sample from a subject;

(b) measuring biogenic polyamine content in the biological sample; wherein a measure of biogenic polyamine content is at least two measures selected from a measure of polyamine content in the biological sample; a measure of aldehyde compound content formed from the polyamine in the biological sample; a measure of polyamine oxidase activity in the biological sample; and a measure of polyamine oxidase protein content in the biological sample; and

(c) comparing the biogenic polyamine content of the biological sample in (b) to polyamine content of a biological sample of a healthy subject, wherein a difference in measured value of the subject in (a) compared to a measured value of a healthy subject ~~or a subject suffering from brain disease other than stroke~~ is indicative of an asymptomatic cerebral infarction.

10. (Previously presented): The method according to claim 9, wherein the at least one biological sample is at least one selected from plasma, urine, saliva, cerebrospinal fluid, and bone marrow fluid.

11. (Currently amended): The method according to claim 9, wherein the biogenic polyamine is metabolized by at least one of oxidation, acetylation, transamination and carbamoylation.

12. (Currently amended): The method according to claim 9, wherein[[,]] the biogenic polyamine is oxidatively deaminated by polyamine oxidase to produce an aldehyde compound.

13. (Currently amended): The method according to claim 9~~13~~, wherein the aldehyde ~~aldwehyde~~ compound is acrolein.

14. (Previously presented): The method according to claim 9, wherein the biogenic polyamine is at least one selected from putrescine, cadaverine, spermidine, spermine, 1,3-diaminopropane, caldine, homospermidine, 3-aminopropylcadaverine, norspermine, thermospermine, and caldopentamine.

15. (Previously presented): The method according to claim 9, wherein the biogenic polyamine is at least one of putrescine, spermidine and spermine.

16. (Currently amended): The method according to claim 9, wherein the at least two measures of biogenic polyamine content comprise a measure of polyamine content and a measure of polyamine oxidase activity.

17. (Previously presented): A screening method to identify a subject that has experienced an asymptomatic cerebral infarction, comprising:

(a) obtaining at least one biological sample from the subject;

(b) measuring biogenic polyamine content in the biological sample; wherein a measure of biogenic polyamine content is at least two measures selected from a measure of polyamine content in the biological sample; a measure of aldehyde compound content formed from the polyamine in the biological sample; a measure of polyamine oxidase activity in the biological sample; and a measure of polyamine oxidase protein content in the biological sample; and

(c) comparing the difference between the measured biogenic polyamine content in (b) to a measured biogenic polyamine content of a healthy subject; wherein the difference in measured value in (c) is indicative of an asymptomatic cerebral infarction.

18. (Previously presented): The method according to claim 17, wherein the at least one biological sample is at least one selected from plasma, urine, saliva, cerebrospinal fluid, and bone marrow fluid.

19. (Previously presented): The method according to claim 17, wherein the biogenic polyamine is metabolized by at least one of oxidation, acetylation, transamination and carbamoylation.

20. (Previously presented): The method according to claim 17, wherein, the biogenic polyamine is oxidatively deaminated by polyamine oxidase to produce an aldehyde compound.

21. (Previously presented): The method according to claim 20, wherein the aldehyde compound is acrolein.

22. (Previously presented): The method according to claim 17, wherein the biogenic polyamine is at least one selected from putrescine, cadaverine, spermidine, spermine, 1,3-diaminopropane, caldine, homospermidine, 3-aminopropylcadaverine, norspermine, thermospermine, and caldopentamine.

23. (Previously presented): The method according to claim 17, wherein the biogenic polyamine is at least one of putrescine, spermidine and spermine.

24. (Previously presented): The method according to claim 17, wherein the at least two measures of biogenic polyamine content comprise a measure of polyamine content and a measure of polyamine oxidase activity.